A5063857442- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Receptor Mechanisms and Signaling
- Radioactive Decay and Measurement Techniques
- Neuroscience and Neuropharmacology Research
- Cancer Research and Treatments
- Chemical Reactions and Isotopes
- Glioma Diagnosis and Treatment
- Pharmacological Receptor Mechanisms and Effects
- Graphite, nuclear technology, radiation studies
- Nuclear and radioactivity studies
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Click Chemistry and Applications
- Synthesis and Biological Evaluation
- Cancer Cells and Metastasis
- Brain Metastases and Treatment
- Mitochondrial Function and Pathology
- Atomic and Subatomic Physics Research
- Synthesis and pharmacology of benzodiazepine derivatives
- Prostate Cancer Treatment and Research
- Genetic Neurodegenerative Diseases
- Pharmacogenetics and Drug Metabolism
- Cancer, Lipids, and Metabolism
Institute of Molecular Bioimaging and Physiology
2002-2024
National Research Council
2006-2024
University of Milano-Bicocca
2014-2024
University of Milan
1992-2014
Istituti di Ricovero e Cura a Carattere Scientifico
2009
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2009
IRCCS Ospedale San Raffaele
2009
Vita-Salute San Raffaele University
2006-2007
San Raffaele University of Rome
1999-2006
University of Catania
2001
This guidance is meant as a to Part B of the EANM "Guidelines on Good Radiopharmacy Practice (GRPP)" issued by Committee (see www.eanm.org ), covering small-scale "in house" preparation radiopharmaceuticals which are not kit procedures. The aim provide more detailed and practice-oriented those who involved in of, for example, PET, therapeutic or other intended commercial purposes distribution.
To fulfil good manufacturing requirements, analytical methods for the analysis of pharmaceuticals human and vetinary use must be validated. The International Conference on Harmonization Technical Requirements Registration Pharmaceuticals Human Use (ICH) has published guidance documents requirements such validation activities these have been adopted by European Medicines Agency, U.S. Food Drug Administration (FDA) other regulatory bodies. These do not, however, fully address all specific...
Abstract This guideline on current good radiopharmacy practice (cGRPP) for small-scale preparation of radiopharmaceuticals represents the view Radiopharmacy Committee European Association Nuclear Medicine (EANM). The is laid out in format EU Good Manufacturing Practice (GMP) guidelines as defined EudraLex volume 4. It intended non-commercial sites such hospital radiopharmacies, nuclear medicine departments, research PET centres and general any healthcare establishments. In first section,...
Abstract Background Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities patient access among different countries, which could be mitigated by improving to and availability of radiopharmaceuticals. Main body This paper summarises major considerations for a suitable pharmaceutical regulatory framework facilitate These include distinct characteristics radiopharmaceuticals require dedicated regulations, considering impact variable...
Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF in multiple experimental models that differ their glycolytic phenotypes to gain insights into optimal modulation metabolic features therapy. Prolonged treatments induced vascular regression necrosis xenograft models, with highly tumors becoming treatment resistant more rapidly than poorly tumors. By PET imaging, prolonged yielded an increase...
This document is meant to complement Part B of the EANM ‘Guidelines on current good radiopharmacy practice (cGRPP) in preparation radiopharmaceuticals’ issued by Radiopharmacy Committee European Association Nuclear Medicine, covering small‐scale in‐house radiopharmaceuticals with automated modules. The aim provide more detailed and practice‐oriented guidance those who are involved radiopharmaceuticals, which not intended for commercial purposes or distribution.
Validation and qualification activities are nowadays an integral part of the day by routine work in a radiopharmacy. This document is meant as Appendix Part B EANM "Guidelines on Good Radiopharmacy Practice (GRPP)" issued Committee EANM, covering validation aspects related to small-scale "in house" preparation radiopharmaceuticals. The aim provide more detailed practice-oriented guidance those who involved radiopharmaceuticals which not intended for commercial purposes or distribution.The...
ADVERTISEMENT RETURN TO ISSUEPREVLetterNEXTDesign, Radiosynthesis, and Biodistribution of a New Potent Selective Ligand for in Vivo Imaging the Adenosine A2A Receptor System Using Positron Emission TomographySergio Todde, Rosa Maria Moresco, Pasquale Simonelli, Pier Giovanni Baraldi, Barbara Cacciari, Giampiero Spalluto, Katia Varani, Angela Monopoli, Mario Matarrese, Assunta Carpinelli, Fulvio Magni, Marzia Galli Kienle, Ferruccio FazioView Author Information CNR-INB, University...
This document is intended as a supplement to the EANM "Guidelines on current Good Radiopharmacy Practice (cGRPP)" issued by Committee of (Gillings et al. in EJNMMI Radiopharm Chem. 6:8, 2021). The aim provide that describes how manage risks associated with small-scale "in-house" preparation radiopharmaceuticals, not for commercial purposes or distribution.
The development of novel radiopharmaceuticals is very rapid and highly innovative both for diagnostic therapeutic applications. translation into the clinic, however, hampered by high regulatory demands in Europe. This article describes main rules, guidelines guidance documents European Union relation to pharmaceutical framework. Until today a great number are introduced clinically using specific national pathways outside clinical trial regulation examples provided. In this context,...
This is a position paper of the Radiopharmacy Committee EANM (European Association Nuclear Medicine) addressing toxicology studies for application new diagnostic and therapeutic radiopharmaceuticals (RP) that are not approved (i.e., having marketing authorization or monograph in European Pharmacopoeia), excluding endogenous ubiquitous substances humans. discusses requirements clinical trials with research applications, necessarily intended to aim at authorization. If intended, scientific...
The novel quinoline-2-carboxamide derivatives N-[methyl-11C]-3-methyl-4-phenyl-N-(phenylmethyl)quinoline-2-carboxamide ([11C]4), (±)-N-[methyl-11C]-3-methyl-N-(1-methylpropyl)-4-phenylquinoline-2-carboxamide ([11C]5), and (±)-N-[methyl-11C]-3-methyl-4-(2-fluorophenyl)-N-(1-methylpropyl)quinoline-2-carboxamide ([11C]6) were labeled with carbon-11 (t1/2 = 20.4 min, β+ 99.8%) as potential radioligands for the noninvasive assessment of peripheral benzodiazepine type receptors (PBR) in vivo...
Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite efforts, response to current therapies poor and 2-years survival rate ranging from 6-12%. Here, we evaluated preclinical efficacy Metformin (MET) as add-on therapy Temozolomide (TMZ) ability [ 18 F]FLT (activity thymidine kinase 1 related cell proliferation) F]VC701 (translocator protein, TSPO) Positron Emission Tomography (PET) radiotracers predict therapy. Indeed, TSPO expressed on outer mitochondrial membrane activated...
Abstract Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in field radiopharmaceutical development. Main body This selection highlights provides 24 different topics selected by each coauthoring member addressing variety aspects ranging from novel radiochemistry first-in-human application radiopharmaceuticals. Conclusion Trends radiopharmacy are highlighted. Hot cover entire scope Chemistry,...
In the last decade development of new PSMA-ligand based radiopharmaceuticals for imaging and therapy prostate cancer has been a highly active important area research. The most promising derivative in terms interaction with antigen clinical properties found to be "PSMA-617", its lutetium-177 radiolabelled version recently approved by EU USA regulatory agencies therapeutic purposes. For above reasons, derivatives PSMA-617 fluorine-18 may still great interest. This paper proposes comparison two...